AN2 Therapeutics, Inc. (ANTX)
5.74
-0.24
(-4.01%)
USD |
NASDAQ |
Sep 09, 11:41
AN2 Therapeutics Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.0001 |
| March 31, 2023 | 0.0004 |
| December 31, 2022 | 0.0006 |
| September 30, 2022 | 0.0007 |
| June 30, 2022 | 0.0001 |
| March 31, 2022 | 0.0003 |
| December 31, 2021 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Cocrystal Pharma, Inc. | 1.284 |
| CNBX Pharmaceuticals, Inc. | -0.4388 |
| GB Sciences, Inc. | -- |
| Arvinas, Inc. | 0.0146 |
| Fulcrum Therapeutics, Inc. | 0.017 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 81.68M |
| Total Liabilities (Quarterly) | 5.755M |
| Shareholders Equity (Quarterly) | 75.92M |
| Current Ratio | 14.32 |